Search research articles
Contact Us
Filters
Showing results (61-70 of 108) with videos related to
Page
of 11
Sort By:
Blood
|
September 19, 2015
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
Jatin J Shah, Edward A Stadtmauer, Rafat Abonour, et al.
Blood Cancer Journal
|
November 4, 2025
Outcomes of relapse after teclistamab therapy in multiple myeloma
Kyle L Yu, Matthew Ho, Luca Paruzzo, et al.
British Journal of Haematology
|
March 13, 2021
B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy
Luca Bernabei, Lifeng Tian, Alfred L Garfall, et al.
Biorxiv : the Preprint Server for Biology
|
February 8, 2024
Human IL-6 fosters long-term engraftment of patient derived disease-driving myeloma cells in immunodeficient mice
Zainul S Hasanali, Alfred L Garfall, Lisa Burzenski, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 5, 2015
Outpatient Autologous Stem Cell Transplantation for Patients With Myeloma
Thomas M Paul, Stephen V Liu, Elise A Chong, et al.
The Lancet. Oncology
|
November 17, 2018
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial
Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, et al.
JCI Insight
|
May 7, 2024
Human IL-6 fosters long-term engraftment of patient-derived disease-driving myeloma cells in immunodeficient mice
Zainul S Hasanali, Alfred L Garfall, Lisa Burzenski, et al.
Cancer Medicine
|
May 16, 2026
Investigating Associations Between Psychological Distress and Changes in Peripheral Blood Monocytes in Patients With CLL/SLL Managed With Active Surveillance
Carolyn Y Fang, Alexander W MacFarlane, Henry C H Fung, et al.
Cancer
|
July 27, 2021
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study
Sagar Lonial, Hans C Lee, Ashraf Badros, et al.
Blood Advances
|
October 3, 2019
T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma
Alfred L Garfall, Ehren K Dancy, Adam D Cohen, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 108) with videos related to
Sort By:
Page
of 11
Blood
|
September 19, 2015
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
Jatin J Shah, Edward A Stadtmauer, Rafat Abonour, et al.
Blood Cancer Journal
|
November 4, 2025
Outcomes of relapse after teclistamab therapy in multiple myeloma
Kyle L Yu, Matthew Ho, Luca Paruzzo, et al.
British Journal of Haematology
|
March 13, 2021
B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy
Luca Bernabei, Lifeng Tian, Alfred L Garfall, et al.
Biorxiv : the Preprint Server for Biology
|
February 8, 2024
Human IL-6 fosters long-term engraftment of patient derived disease-driving myeloma cells in immunodeficient mice
Zainul S Hasanali, Alfred L Garfall, Lisa Burzenski, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 5, 2015
Outpatient Autologous Stem Cell Transplantation for Patients With Myeloma
Thomas M Paul, Stephen V Liu, Elise A Chong, et al.
The Lancet. Oncology
|
November 17, 2018
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial
Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, et al.
JCI Insight
|
May 7, 2024
Human IL-6 fosters long-term engraftment of patient-derived disease-driving myeloma cells in immunodeficient mice
Zainul S Hasanali, Alfred L Garfall, Lisa Burzenski, et al.
Cancer Medicine
|
May 16, 2026
Investigating Associations Between Psychological Distress and Changes in Peripheral Blood Monocytes in Patients With CLL/SLL Managed With Active Surveillance
Carolyn Y Fang, Alexander W MacFarlane, Henry C H Fung, et al.
Cancer
|
July 27, 2021
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study
Sagar Lonial, Hans C Lee, Ashraf Badros, et al.
Blood Advances
|
October 3, 2019
T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma
Alfred L Garfall, Ehren K Dancy, Adam D Cohen, et al.
Page
of 11